Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

AMB302

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Aimed Bio, GeneQuantum Healthcare

Drug class:

Topoisomerase I inhibitor, FGFR3-targeted antibody-drug conjugate

Related drugs:

FGFR3 overexpression	Bladder Cancer	FGFR3 overexpression	Bladder Cancer	AMB302 Sensitive: D – Preclinical AACR 2023 - 1 week (New D) AMB302 Sensitive : D AACR 2023 - 1wk	AMB302 Sensitive: D – Preclinical AACR 2023 - 1 week AMB302 Sensitive : D AACR 2023 - 1 week - (New D)
FGFR3 overexpression	Glioblastoma	FGFR3 overexpression	Glioblastoma	AMB302 Sensitive: D – Preclinical AACR 2023 - 1 week (New D) AMB302 Sensitive : D AACR 2023 - 1wk	AMB302 Sensitive: D – Preclinical AACR 2023 - 1 week AMB302 Sensitive : D AACR 2023 - 1 week - (New D)
FGFR3-TACC3 fusion	Bladder Cancer	FGFR3-TACC3 fusion	Bladder Cancer	AMB302 Sensitive: D – Preclinical AACR 2023 - 1 week (New D) AMB302 Sensitive : D AACR 2023 - 1wk	AMB302 Sensitive: D – Preclinical AACR 2023 - 1 week AMB302 Sensitive : D AACR 2023 - 1 week - (New D)
FGFR3-TACC3 fusion	Glioblastoma	FGFR3-TACC3 fusion	Glioblastoma	AMB302 Sensitive: D – Preclinical AACR 2023 - 1 week (New D) AMB302 Sensitive : D AACR 2023 - 1wk	AMB302 Sensitive: D – Preclinical AACR 2023 - 1 week AMB302 Sensitive : D AACR 2023 - 1 week - (New D)